Cargando…

Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial

AIMS/INTRODUCTION: Metformin is associated with the risk of gastrointestinal complications, and probiotic Bifidobacterium bifidum G9‐1 (BBG9‐1) can improve the symptoms of diarrhea. This study aimed to clarify the effects of probiotic BBG9‐1 on the gastrointestinal symptoms of type 2 diabetes mellit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hata, Shinnosuke, Nakajima, Hanako, Hashimoto, Yoshitaka, Miyoshi, Tomoki, Hosomi, Yukako, Okamura, Takuro, Majima, Saori, Nakanishi, Naoko, Senmaru, Takafumi, Osaka, Takafumi, Okada, Hiroshi, Ushigome, Emi, Hamaguchi, Masahide, Asano, Mai, Yamazaki, Masahiro, Fukui, Michiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902400/
https://www.ncbi.nlm.nih.gov/pubmed/34665938
http://dx.doi.org/10.1111/jdi.13698
_version_ 1784664591464136704
author Hata, Shinnosuke
Nakajima, Hanako
Hashimoto, Yoshitaka
Miyoshi, Tomoki
Hosomi, Yukako
Okamura, Takuro
Majima, Saori
Nakanishi, Naoko
Senmaru, Takafumi
Osaka, Takafumi
Okada, Hiroshi
Ushigome, Emi
Hamaguchi, Masahide
Asano, Mai
Yamazaki, Masahiro
Fukui, Michiaki
author_facet Hata, Shinnosuke
Nakajima, Hanako
Hashimoto, Yoshitaka
Miyoshi, Tomoki
Hosomi, Yukako
Okamura, Takuro
Majima, Saori
Nakanishi, Naoko
Senmaru, Takafumi
Osaka, Takafumi
Okada, Hiroshi
Ushigome, Emi
Hamaguchi, Masahide
Asano, Mai
Yamazaki, Masahiro
Fukui, Michiaki
author_sort Hata, Shinnosuke
collection PubMed
description AIMS/INTRODUCTION: Metformin is associated with the risk of gastrointestinal complications, and probiotic Bifidobacterium bifidum G9‐1 (BBG9‐1) can improve the symptoms of diarrhea. This study aimed to clarify the effects of probiotic BBG9‐1 on the gastrointestinal symptoms of type 2 diabetes mellitus patients using metformin. MATERIALS AND METHODS: In this open‐label single‐arm exploratory study, 40 patients (mean age 64.0 ± 9.4 years) were given probiotic BBG9‐1 for 10 weeks. Changes in the gastrointestinal symptom rating scale total score, which was the primary end‐point, gastrointestinal symptom rating scale subscale scores, glycated hemoglobin levels and gut microbiota after the administration of probiotic BBG9‐1 were evaluated by the Student's t‐test. RESULTS: The gastrointestinal symptom rating scale total score significantly improved (from 2.02 ± 0.51 to 1.59 ± 0.43, change, −0.43 ± 0.49, P < 0.001). Furthermore, all gastrointestinal symptom rating scale subscale scores, including diarrhea (from 2.32 ± 1.14 to 1.89 ± 0.99, change, −0.42 ± 0.95, P = 0.007) and constipation (from 3.00 ± 1.16 to 2.20 ± 1.07, change, −0.80 ± 1.19, P < 0.001), scores also significantly improved. However, the glycated hemoglobin levels did not change (from 7.0 ± 0.7 to 7.0 ± 0.6%, change, 0.0 ± 0.4, P = 0.91). The relative abundance of the genus Sutterella decreased by the use of probiotic BBG9‐1 (from 0.011 ± 0.009 to 0.008 ± 0.006, change, −0.003 ± 0.006, P = 0.002). CONCLUSIONS: Type 2 diabetes mellitus patients treated with metformin showed significant improvement in all gastrointestinal symptom rating scores after using probiotic BBG9‐1 without changing the glucose control. This study showed the potential usefulness of probiotic BBG9‐1 for improving gastrointestinal symptoms, including constipation and diarrhea, in type 2 diabetes mellitus patients treated with metformin.
format Online
Article
Text
id pubmed-8902400
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89024002022-03-11 Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial Hata, Shinnosuke Nakajima, Hanako Hashimoto, Yoshitaka Miyoshi, Tomoki Hosomi, Yukako Okamura, Takuro Majima, Saori Nakanishi, Naoko Senmaru, Takafumi Osaka, Takafumi Okada, Hiroshi Ushigome, Emi Hamaguchi, Masahide Asano, Mai Yamazaki, Masahiro Fukui, Michiaki J Diabetes Investig Articles AIMS/INTRODUCTION: Metformin is associated with the risk of gastrointestinal complications, and probiotic Bifidobacterium bifidum G9‐1 (BBG9‐1) can improve the symptoms of diarrhea. This study aimed to clarify the effects of probiotic BBG9‐1 on the gastrointestinal symptoms of type 2 diabetes mellitus patients using metformin. MATERIALS AND METHODS: In this open‐label single‐arm exploratory study, 40 patients (mean age 64.0 ± 9.4 years) were given probiotic BBG9‐1 for 10 weeks. Changes in the gastrointestinal symptom rating scale total score, which was the primary end‐point, gastrointestinal symptom rating scale subscale scores, glycated hemoglobin levels and gut microbiota after the administration of probiotic BBG9‐1 were evaluated by the Student's t‐test. RESULTS: The gastrointestinal symptom rating scale total score significantly improved (from 2.02 ± 0.51 to 1.59 ± 0.43, change, −0.43 ± 0.49, P < 0.001). Furthermore, all gastrointestinal symptom rating scale subscale scores, including diarrhea (from 2.32 ± 1.14 to 1.89 ± 0.99, change, −0.42 ± 0.95, P = 0.007) and constipation (from 3.00 ± 1.16 to 2.20 ± 1.07, change, −0.80 ± 1.19, P < 0.001), scores also significantly improved. However, the glycated hemoglobin levels did not change (from 7.0 ± 0.7 to 7.0 ± 0.6%, change, 0.0 ± 0.4, P = 0.91). The relative abundance of the genus Sutterella decreased by the use of probiotic BBG9‐1 (from 0.011 ± 0.009 to 0.008 ± 0.006, change, −0.003 ± 0.006, P = 0.002). CONCLUSIONS: Type 2 diabetes mellitus patients treated with metformin showed significant improvement in all gastrointestinal symptom rating scores after using probiotic BBG9‐1 without changing the glucose control. This study showed the potential usefulness of probiotic BBG9‐1 for improving gastrointestinal symptoms, including constipation and diarrhea, in type 2 diabetes mellitus patients treated with metformin. John Wiley and Sons Inc. 2021-11-15 2022-03 /pmc/articles/PMC8902400/ /pubmed/34665938 http://dx.doi.org/10.1111/jdi.13698 Text en © 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Articles
Hata, Shinnosuke
Nakajima, Hanako
Hashimoto, Yoshitaka
Miyoshi, Tomoki
Hosomi, Yukako
Okamura, Takuro
Majima, Saori
Nakanishi, Naoko
Senmaru, Takafumi
Osaka, Takafumi
Okada, Hiroshi
Ushigome, Emi
Hamaguchi, Masahide
Asano, Mai
Yamazaki, Masahiro
Fukui, Michiaki
Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial
title Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial
title_full Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial
title_fullStr Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial
title_full_unstemmed Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial
title_short Effects of probiotic Bifidobacterium bifidum G9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open‐label, single‐arm, exploratory research trial
title_sort effects of probiotic bifidobacterium bifidum g9‐1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: an open‐label, single‐arm, exploratory research trial
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902400/
https://www.ncbi.nlm.nih.gov/pubmed/34665938
http://dx.doi.org/10.1111/jdi.13698
work_keys_str_mv AT hatashinnosuke effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT nakajimahanako effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT hashimotoyoshitaka effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT miyoshitomoki effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT hosomiyukako effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT okamuratakuro effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT majimasaori effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT nakanishinaoko effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT senmarutakafumi effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT osakatakafumi effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT okadahiroshi effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT ushigomeemi effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT hamaguchimasahide effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT asanomai effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT yamazakimasahiro effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial
AT fukuimichiaki effectsofprobioticbifidobacteriumbifidumg91onthegastrointestinalsymptomsofpatientswithtype2diabetesmellitustreatedwithmetforminanopenlabelsinglearmexploratoryresearchtrial